Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Neurochem ; 158(5): 1110-1130, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34254317

RESUMEN

Bone cancer pain (BCP) is a clinical pathology that urgently needs to be solved, but research on the mechanism of BCP has so far achieved limited success. Nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) has been shown to be involved in pain, but its involvement in BCP and the specific mechanism have yet to be examined. This study aimed to test the hypothesis that BCP induces the transfer of Nrf2 from the cytoplasm to the nucleus and further promotes nuclear transcription to activate heme oxygenase-1 (HO-1) and inhibit the activation of nuclear factor-kappa B (NF-κB) signalling, ultimately regulating the neuroinflammatory response. Von-Frey was used for behavioural analysis in rats with BCP, whereas western blotting, real-time quantitative PCR (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) were used to detect molecular expression changes, and immunofluorescence was used to detect cellular localization. We demonstrated that BCP induced increased Nrf2 nuclear protein expression with decreased cytoplasmic protein expression in the spinal cord. Further increases in Nrf2 nuclear protein expression can alleviate hyperalgesia and activate HO-1 to inhibit the expression of NF-κB nuclear protein and inflammatory factors. Strikingly, intrathecal administration of the corresponding siRNA reversed the above effects. In addition, the results of double immune labelling revealed that Nrf2 and NF-κB were coexpressed in spinal cord neurons of rats with BCP. In summary, these findings suggest that the entry of Nrf2 into the nucleus promotes the expression of HO-1, inhibiting activation of the NF-κB signalling pathway, reducing neuroinflammation and ultimately exerting an anti-nociceptive effect.


Asunto(s)
Neoplasias Óseas/metabolismo , Dolor en Cáncer/metabolismo , Hiperalgesia/metabolismo , Factor 2 Relacionado con NF-E2/biosíntesis , FN-kappa B/metabolismo , Médula Espinal/metabolismo , Transporte Activo de Núcleo Celular/fisiología , Animales , Neoplasias Óseas/patología , Dolor en Cáncer/patología , Línea Celular Tumoral , Núcleo Celular/metabolismo , Femenino , Hiperalgesia/patología , FN-kappa B/antagonistas & inhibidores , Neuronas/metabolismo , Neuronas/patología , Ratas , Ratas Sprague-Dawley , Médula Espinal/patología
2.
Neurosci Lett ; 714: 134595, 2020 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31682872

RESUMEN

The pathogenesis of cancer induced bone pain (CIBP) is extremely complex, and glutamate receptor dysfunction plays an important role in the formation of CIBP. Synapse-associated protein 102 (SAP102) anchors glutamate receptors in the postsynaptic membrane. However, its effect on hyperalgesia formation in CIBP has not been clarified. This study investigated the role of SAP102 in the formation of hyperalgesia in rats with CIBP SAP102 is present in spinal dorsal horn neurons, but not in astrocytes or microglia. NMDAR-NR2B is localized with neurons. In addition, SAP102 and NMDAR-NR2B expression levels in spinal dorsal horn tissues were detected by Western blot and co-immunoprecipitation. Intrathecal injection of lentiviral vector of RNAi to knockdown SAP102 expression in the spinal dorsal horn significantly attenuated abnormal mechanic pain when compared to non-coding lentiviral vector. These findings indicate that SAP102 can anchor NMDA receptors to affect hyperalgesia formation in bone cancer pain.


Asunto(s)
Neoplasias Óseas/complicaciones , Dolor en Cáncer/genética , Carcinoma 256 de Walker/complicaciones , Hiperalgesia/genética , Neuropéptidos/genética , Receptores de N-Metil-D-Aspartato/metabolismo , Tibia , Animales , Neoplasias Óseas/secundario , Dolor en Cáncer/etiología , Dolor en Cáncer/metabolismo , Carcinoma 256 de Walker/secundario , Femenino , Técnicas de Silenciamiento del Gen , Hiperalgesia/etiología , Hiperalgesia/metabolismo , Neuropéptidos/metabolismo , Células del Asta Posterior/metabolismo , Ratas , Asta Dorsal de la Médula Espinal/metabolismo
3.
Mol Med Rep ; 20(5): 4695-4705, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31702022

RESUMEN

Treatment of cancer­induced bone pain (CIBP) is challenging in clinical settings. Oxycodone (OXY) is used to treat CIBP; however, a lack of understanding of the mechanisms underlying CIBP limits the application of OXY. In the present study, all rats were randomly divided into three groups: The sham group, the CIBP group, and the OXY group. Then, a rat model of CIBP was established by inoculation of Walker 256 tumor cells from rat tibia. Phosphoproteomic profiling of the OXY­treated spinal dorsal cords of rats with CIBP was performed, and 1,679 phosphorylated proteins were identified, of which 160 proteins were significantly different between the CIBP and sham groups, and 113 proteins were significantly different between the CIBP and OXY groups. Gene Ontology analysis revealed that these proteins mainly clustered as synaptic­associated cellular components; among these, disks large homolog 3 expression was markedly increased in rats with CIBP and was reversed by OXY treatment. Subsequent domain analysis of the differential proteins revealed several significant synaptic­associated domains. In conclusion, synaptic­associated cellular components may be critical in OXY­induced analgesia in rats with CIBP.


Asunto(s)
Dolor en Cáncer , Proteínas de Neoplasias/biosíntesis , Neoplasias Experimentales , Oxicodona/farmacología , Fosfoproteínas/biosíntesis , Proteómica , Neoplasias de la Columna Vertebral , Animales , Dolor en Cáncer/tratamiento farmacológico , Dolor en Cáncer/metabolismo , Dolor en Cáncer/patología , Femenino , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología , Ratas , Ratas Sprague-Dawley , Neoplasias de la Columna Vertebral/tratamiento farmacológico , Neoplasias de la Columna Vertebral/metabolismo , Neoplasias de la Columna Vertebral/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA